Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)

Overview of attention for article published in Journal of Clinical Oncology, October 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet
twitter: 13 X users

reddit: 1 Redditor
bluesky: 1 Bluesky user

Readers on

mendeley: 22 Mendeley

So far, Altmetric has seen 1 Bluesky post from an account with 257 followers.

Open Access UCL Research: Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018) discovery.ucl.ac.uk/id/eprint/10...

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.